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Abstract 
Neuropsychology malingering base rates have not been widely investigated in Australia. 
Estimates in North America vary with as many as 4 in 10 people evaluated for personal injury 
or compensation cases suspected of exaggerating symptoms. Data on Australian 
neuropsychology symptom exaggeration base rates were estimated using a modified and 
expanded version of a survey previously designed for this purpose (Mittenberg, Patton, 
Canyock, & Condit, 2002). Figures were based on an estimated 1818 annual cases involved in 
personal injury, (n = 542), disability (n = 109), criminal (n = 108), or medical (n = 1059) 
matters. Symptom exaggeration base rates associated with referral type and diagnoses were 
variable. Specifically, 17% of criminal, 13% of personal injury, 13% of disability or workers 
compensation, and 4% of medical or psychiatric cases were reported to involve symptom 
exaggeration or probable symptom exaggeration. The highest rates of symptom exaggeration 
included cases referred for mild head injury (23%), pain or somatoform disorders (15%), 
moderate to severe head injury (15%), and fibromyalgia or chronic fatigue (15%). Overall, 
Australian symptom exaggeration base rates reported in this study were lower compared to 
base rates previously reported in North America.  
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Symptom exaggeration base rates and detection methods in Australia 
For the average clinician, a formal evaluation of symptom exaggeration is not a 
routine component of a neuropsychological assessment, and is only considered when 
suspicion is raised during the testing session (Franzen & Iverson, 1998). Although the 
importance of routinely screening for symptom exaggeration in personal injury cases is 
widely recognised (e.g., Bianchini, Mathias, & Greve, 2001; Doss, Chelune, & Naugle, 1999; 
Green, Rohling, Lees-Haley, & Allen, 2001; Iverson & Binder, 2000; Iverson & Franzen, 
1996; Langeluddecke & Lucas, 2003; Mateer, 2000; Millis, Ross, & Ricker, 1998; Slick, 
Hopp, Strauss, & Spellacy, 1996; Spreen & Strauss, 1998; Suhr & Boyer, 1999; Sweet, 1999), 
screening for symptom exaggeration in the absence of litigation is far from routine clinical 
practice.  
An understanding of symptom exaggeration base rates in specific clinical settings is 
critical for encouraging good assessment practices among clinicians. If the frequency of 
symptom exaggeration can be determined in clinical settings where symptom exaggeration is 
not considered a common occurrence (e.g., medical hospital), this may encourage 
practitioners to routinely employ appropriate measures to screen for exaggeration. In clinical 
settings where symptom exaggeration is more common (e.g., personal injury litigation), the 
knowledge of symptom exaggeration base rates helps the clinician to (a) determine an 
appropriate management strategy (by informing decisions about cutoff score for detection 
tests), and (b) determine how confident clinicians can be that a test result does in fact reflect 
exaggeration. For example, it is well known that positive predictive power values and other 
test operating characteristics vary depending on the base rate of symptom exaggeration1. For 
the clinician, the lack of consideration of symptom exaggeration base rates may ultimately 
lead to the misidentification of individuals attempting to exaggerate or feign impairment. 
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 To date, the majority of research providing symptom exaggeration base rates has 
focused on individuals assessed in neuropsychological settings throughout North America. 
Larrabee (2003) examined 11 North American-based empirical studies that included a pooled 
sample of 1363 consecutive referrals seeking compensation for mild head injury. Based on the 
pooled sample, the base rate of symptom exaggeration was 40% (range: 15%- 64%). In a 
recent large scale survey of the American Board of Clinical Neuropsychology membership, 
Mittenberg et al. (2002) reported estimated base rates from 131 respondents that included 
33,531 annual neuropsychological cases involved in personal injury (n = 6,371), disability (n 
= 3,688), criminal (n = 1,341), and medical (n = 22,131) matters. Mittenberg and colleagues 
found that the average reported base rate of symptom exaggeration was 29% in personal 
injury, 30% in disability, 19% in criminal, and 8% in medical cases. Symptom exaggeration 
base rates tended to be higher in some clinical samples than others, with the highest base rates 
of malingering found in individuals referred for mild head injury (39%), fibromyalgia/chronic 
fatigue (35%), and chronic pain (31%). Overall, the North American literature suggests that 
the rate of symptom exaggeration is variable with fluctuations associated with setting, referral 
type, and diagnosis. Typically estimates of symptom exaggeration in personal injury cases 
suggest it ranges between 20 to 35% (Mittenberg et al., 2002).  
 The degree to which Australians presenting for neuropsychological assessment 
exaggerate their current level of functioning has been examined in a handful of studies only.  
These studies suggest that the base rate of symptom exaggeration in Australia, based on 
estimates derived from the Wechsler Memory Scale-III Rarely Missed Index (WMS-III RMI) 
is lower than reported in North America. Reported base rates of symptom exaggeration range 
from 12.7% in a sample of 158 personal injury litigants (Lange, Anderson, & Sullivan, in 
press)2 to 28% in 99 mild head injury litigants (Langeluddecke & Lucas, 2004). However, 
these base rates may not accurately reflect the true rate of malingering in these samples 
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because these base rates were derived from the performance on a single validity test only 
(e.g., TOMM or WMRT).  Information regarding base rates in Australia is extremely limited 
and requires further systematic examination.  The purpose of this study was to replicate and 
expand Mittenberg et al.’s symptom exaggeration base rate study in Australia. There were 
three primary aims. First, to establish the base rate of symptom exaggeration in Australia. 
Second, to compare the base rates from Australia to those reported in North America. Third, 
to determine what methods of symptom exaggeration detection are commonly used by 
Australian clinicians.  
Method 
Measures 
Measures included a modified and expanded version of Mittenberg and colleagues 
“Survey on Probable Malingering and Symptom Exaggeration” (Mittenberg et al., 2002). The 
original survey was modified for use in Australia by (a) substituting Australian states for 
North American geographical regions, and (b) relabelling clinical practice settings using local 
terminology. The original survey was expanded in five ways. First, two questions were 
included aimed at gathering information regarding the methods and specific tests used by 
clinicians to screen for symptom exaggeration. Second, one question was included regarding 
membership to national and international professional organisations. Third, participants were 
instructed to complete the survey using a database rather than by using a “best guess”. An 
item was also included for participants to indicate whether they had completed the survey by 
consulting a data base or using a “best guess” method. Fourth, an item was included to assess 
the extent of screening for symptom exaggeration routinely undertaken with litigating and 
non-litigating clients.  Finally, a “minimal response option” was included on the survey 
requesting details of practice characteristics and reasons for not completing the full survey to 
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enable comparisons between those who completed the full survey and those who did not. The 
survey used in this study is presented in the Appendix. 
Symptom exaggeration in Australia 7 
Procedure 
 Two recruitment strategies were adopted for data collection (a) emailing members (n 
= 250, including 170 full members) of the Australian Psychological Society [APS], College of 
Clinical Neuropsychology [CCN], and (b) inviting delegates from two neuropsychology 
conferences to participate. Conferences included the Australasian Society for the Study of 
Brain Injury (ASSBI)/International Neuropsychological Society (INS) conference [July, 
2004], and the APS, CCN annual conference [November, 2004]. Survey promotion strategies 
used at these conferences included: periodic announcements about the survey during sessions, 
advertisements on the conference noticeboard, staffing the survey return/distribution area 
(INS only), and placing flyers on delegates seats and satchels (CCN only).  
A total of 17 surveys were returned by participants. Four responses were received after 
the ASSBI/INS conference, nine responses following distribution via the CCN email list, and 
the remaining four responses after the CCN conference. One participant could not estimate 
base rates because they felt their practice did not involve a significant number of litigating or 
compensation seeking clients (minimal response option completed only). Data from two 
participants had to be excluded because of inconsistencies. For example, these participants 
reported they did not see criminal cases, but provided estimates of probable symptom 
exaggeration for such cases. Thus, prevalence estimates were based on 14 surveys. 
Comparisons between minimal responders (n = 1) and others who completed the entire survey 
could not be undertaken.     
Prevalence estimates were calculated using the method employed by Mittenberg et al. 
(2002). Annual figures were derived by multiplying by 12 the number of respondents by the 
mean number of assessment types per month (e.g., criminal, medical and so on). Prevalence 
estimates were therefore based on an estimated 1818 annual cases3 involved in personal 
injury, (n = 542), disability (n = 109), criminal (n = 108), or medical (n = 1059) issues. Only 
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three participants supplied information directly from a database; most participants (n = 11) 
provided their best estimate of practice statistics. 
Results 
Demographic characteristics of the survey respondents are presented in Table 1. 
Relatively few APS CCN members participated in this study, however the geographic 
distribution of those who did participate did not differ significantly from that of the APS CCN 
membership (χ² [3, 12] = 2.434, p>.05). Respondents had been practicing neuropsychology 
for an average of 13.6 years (SD = 8.7), and interpreted an average of 10.8 (SD = 6.2) 
examinations per month. The majority of the participants were from New South Wales and 
Victoria (72% combined). Approximately two thirds of the sample (64%) was in private 
practice. Most of the assessments conducted by participants (almost 60%) did not involve 
clients seeking financial gain. Similar figures were obtained by Mittenberg et al. (2002) who 
reported approximately 50% of respondents involved in private practice and 60% of cases 
involved non-litigating psychiatric or medical evaluations. Of those cases involved in 
personal injury or disability claims (approximately 30%), 73% of cases were referred by a 
plaintiff physician or attorney versus 24% referred by a defendant attorney or insurer. 
_____________________________ 
Insert Table 1 about here 
_____________________________ 
The percentage of annual cases identified as probable symptom exaggerators by 
practice setting and by referral type is presented in Table 2. Estimated symptom exaggeration 
base rates ranged from 3.5% to 17% depending on referral type. The highest base rate was 
reported for criminal cases (17%), followed by personal injury and disability cases (both 
13%), and medical or psychiatric cases (3%). Across practice setting, base rates ranged from 
3% to 17%. The highest estimated base rate was reported in criminal cases seen in private 
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practice (19%) followed by civil cases (13%) seen in a private or group practice. The lowest 
estimated base rates were reported for medical or psychiatric cases not involved in litigation 
or compensation in both private (4%) and hospital (3%) settings  
_____________________________ 
Insert Table 2 about here 
_____________________________ 
Symptom exaggeration base rate information by diagnostic category is presented in 
Table 3. Using the percentage of reported diagnoses associated with symptom exaggeration, a 
rank was assigned to each diagnosis type. Ranks were obtained in a way similar to Mittenberg 
et al. (2002) to show the frequency of endorsement of diagnostic categories identified in that 
study. For comparative purposes, the ranked position for each diagnosis presented by 
Mittenberg and colleagues is also included.  The highest rates of symptom exaggeration 
included cases referred for mild head injury (23%), followed by pain or somatoform 
disorders, moderate to severe head injury, and fibromyalgia or chronic fatigue (15% in each 
of these cases). The lowest base rates were found in cases involving vascular dementia (8%) 
and seizure disorders (9%). These rankings were generally similar to those reported by 
Mittenberg et al., with the exception of the moderate to severe head injury cases (ranked third 
in this study and tenth by Mittenberg et al., 2002). 
_____________________________ 
Insert Table 3 about here 
_____________________________ 
The percentage of respondents who endorsed using various indicators to support the 
detection of symptom exaggeration is presented in Table 4.  Respondents reported using a 
range of potential markers to screen for symptom exaggeration. Ranks of the importance of 
indicators for this study and that of Mittenberg et al. (2002) are also provided for comparison. 
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Specifically, the average respondent considered 6.6 (SD = 1.7) out of nine possible indicators 
of symptom exaggeration when forming an opinion about symptom exaggeration. The most 
frequently endorsed indicator considered by respondents was the severity of cognitive 
impairment inconsistent with the condition (68%), the pattern of cognitive test performance 
inconsistent with the condition (66%), discrepancies among records, self-report, and observed 
behaviour (64%), and the use of forced choice measures using scores below empirical cutoffs 
(59%). The least frequently endorsed methods were: use of validity scale cutoffs on objective 
personality tests (24%); scores below chance on forced choice tests (32%); and, scores below 
empirical cutoffs on other symptom exaggeration tests (30%). The ranking for these measures 
was again generally commensurate with those reported by Mittenberg et al. (2002). 
 _____________________________ 
Insert Table 4 about here 
_____________________________ 
The percentage of respondents who endorsed using specific symptom exaggeration 
tests and indices derived from standard neuropsychological tests is presented in Table 5. The 
two most frequently used tests of symptom exaggeration were the Rey 15-item (See Spreen & 
Strauss, 1998; 46%) and the Test of Memory Malingering (Tombaugh, 1996; 41%). The most 
frequently used symptom exaggeration indices derived from standard neuropsychological 
tests (i.e., in-test methods) were recognition scores from the Rey Auditory Verbal Learning 
Test (Rey, 1964; 24%), the Rarely Missed Index derived from Logical Memory Recognition 
subtests of the Wechsler Memory Scale-Third Edition (WMS-III; Psychological Corporation, 
1997; 15%), and discrepancy scores between attention and memory indexes on the Wechsler 
Memory Scales (14%). Twenty-two percent of the sample endorsed using other symptom 
exaggeration tests not included on the survey. Specifically, each of the following tests was 
endorsed by at least one participant: (a) Hopkins Verbal Learning Test forced choice 
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recognition data [Brandt, 1991], (b) Rawlings Simulation Index (Rawlings & Brooks, 1990), 
and (c) Portland Digit Recognition Test [Binder, 1990]. Two participants reported using either 
their own “validated” test or a structured interview, though these remained unspecified. Use 
of in-test methods used to detect symptom exaggeration not otherwise listed in Table 6 were 
also reported by a small number of participants (n = 4). These were the (a) “general pattern of 
performance and WMS-III RS and list recognition”, (b) SCL-90-R, and (c) “Auditory 
recognition II raw score < 43.” Of the 14 respondents, 84.6% routinely screen for symptom 
exaggeration in litigation/compensation cases, while 38.5% routinely screen for cases that do 
not involve in litigation/compensation.  
_____________________________ 
Insert Table 5 about here 
_____________________________ 
Discussion 
Comparison of the base rates of symptom exaggeration in personal injury cases 
reported in this study (i.e., 13%), reveal that these results are consistent with symptom 
exaggeration base rates reported in only one of the two previously published symptom 
exaggeration studies using personal injury cases in Australia (12.7%; Lange et al., in press). 
Base rates of symptom exaggeration reported by Langeludducke and Lucas, 2003 (i.e., 29%) 
were substantially higher compared to these results. It is not clear why the results of 
Langeluddecke and Lucas are higher than other Australian base rate estimates. Both previous 
studies were based on data from one or two practices only and were similar to each other in 
this regard. Both used consecutive case methods to determine study entry, and although both 
previous studies were conducted in different States, regional differences in base rates were not 
found in this study. It is possible that the discrepancy between these two studies is a 
consequence of the difference in head injury severity of the two samples. Lange et al. 
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examined participants with head injury severity ranging from mild to severe, while 
Langeluddecke and Lucas examined participates with mild head injury only. In this regard, 
when base rates are compared to specific diagnostic groups, the 29% base rate reported by 
Langeluddecke and Lucas in their sample of mild head injury litigants is actually 
commensurate to base rates found in this study for the same patient population (i.e., 23%).  
Compared to malingering base rates reported in North America, the results of this 
study suggest that symptom exaggeration base rates in personal injury and other case types 
may be lower in Australia compared to similar North American settings, although associated 
trends may be similar. For example, the three diagnoses most frequently associated with 
symptom exaggeration in the study by Mittenberg et al., (2002) were the same as those 
reported in this study (i.e., head injury, fibromyalgia/CFS, and pain or somatoform disorders). 
In addition, use of multiple symptom exaggeration indices was reported in both studies and 
diagnostic impressions were supported in 50% or more of symptom exaggeration cases by 
similar indicators (namely, the level and pattern of performance relative to presenting 
condition, scores below cut-offs on forced choice tests, and discrepancies across data 
sources). This suggests that the general approach to symptom exaggeration detection adopted 
by Australian and North American neuropsychologists is similar, and that there are 
similarities in the presenting diagnoses of probable malingerers in both countries.  
Despite similarities in trends associated with this data, it is important to consider why 
the symptom exaggeration base rates might be lower in Australia than in North America.  A 
possible explanation for this discrepancy is the difference between the Australian and North 
American personal injury litigation systems.  For example, in Australia the loser of such 
litigation usually pays the expenses of both sides (whereas in North America the plaintiff pays 
no legal expenses if no settlement is awarded).  In addition, in Australia settlement amounts 
may be limited by law with the effect that the maximum amount payable in the United States 
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is likely to be substantially higher than it is in Australia.  These differences in the potential 
monetary rewards and costs associated with malingering may at least partly account for 
differential rates of malingering in these two countries. 
A second reason that could account for the lower rate of reported symptom 
exaggeration in our study compared to Mittenberg’s relates to the source of referrals 
(Mittenberg et al., 2002).  Specifically, Mittenberg et al.  showed a significant negative 
association between the proportion of plantiff referrals and malingering base rates.  The more 
plantiff cases seen, the lower the estimate of malingering reported.  In our study, most 
referrals were from plantiffs (77%) and this could explain why the malingering base rate in 
our study was lower than that reported in the previous North American study. 
The base rate of symptom exaggeration in general medical settings also deserves 
comment.  Whilst the base rate of symptom exaggeration in Australian medical settings (3 to 
4%) was lower than reported previously in North America (8%; Mittenberg et al., 2002), this 
represents a reasonable proportion of cases.  That is, between 1 in 25 and 1 in 30 persons seen 
for medical or psychiatric assessments may be exaggerating symptoms depending on the 
setting (i.e., private/group practice versus hospital).  Further, whilst the percentage of 
practitioners reporting the use of symptom exaggeration detection tasks with non-litigating 
clients was relatively high in this study (approximately 40%), this level was about half that for 
litigating clients.  There may be a need for increased screening for symptom exaggeration in 
non-litigating groups and this study provides an indication of diagnostic categories where 
such screening may be particularly important.   
In terms of methods used to detect malingerers, the Test of Memory Malingering 
(TOMM) and Rey 15-item test appear to be the most frequently used test by Australian 
neuropsychologists to screen for symptom exaggeration. Whilst the TOMM is generally 
regarded as a useful measure for this purpose (e.g., Powell, Gfeller, Hendricks, & Sharland, 
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2004; Ashendorf, Constantinou, & McCaffrey, 2004; Hill, Ryan, Kennedy, & Malamut, 2003; 
Rees, Tombaugh, & Boulay, 2001; Rees, Tombaugh, Gansler, & Moczynski, 1998; 
Tombaugh, 1997; Tan, Slick, Strauss, & Hultsch, 2002; van Hout, Schmand, Wekking, 
Hageman, & Deelman, 2003), the Rey 15-item test has been widely criticized and is generally 
not recommended (e.g., Griffen, Glassmire, Henderson, & McCann, 1997; Millis & Kler, 
1995; Rogers, Harrell, & Liff, 1993; Schretlen, Brandt, & Krafft, 1991; Vickery, Berry, 
Inman, Harris, & Orey, 2001). The preference for using the Rey-15 item test to screen for 
response bias is of concern, and may have artificially inflated the estimates of malingering 
recorded in this study. 
Use of “in-test” symptom exaggeration detection methods (i.e., methods derived from 
standard clinical tests) was also reported by participants in this sample, and the most 
frequently endorsed method was the RAVLT recognition score (24%). Of particular interest 
was the frequency of respondents who endorsed using methods that include the Digit Span 
subtest (Reliable Digits = < 1%; Vocab-Digit Span discrepancy scores = 7%) and the Rarely 
Missed Index (RMI; 15%) to detect exaggeration. The frequency of using Digit Span methods 
was surprisingly low considering the large body of research suggesting that low digit span 
performance is associated with poor effort (e.g., Axelrod & Rawlings, 1999; Bernard, 1990; 
Binder & Willis, 1991; Greiffenstein, Baker, & Gola, 1994; Greve, Bianchini, Mathias, 
Houston, & Crouch, 2003; Iverson & Franzen, 1994, 1996; Iverson & Tulsky, 2003; Meyers, 
Galinsky, & Volbrecht, 1999; Meyers & Volbrecht, 1999; Millis et al., 1998; Mittenberg, 
Theroux-Fichera, Zielinski, & Heilbronner, 1995; Suhr, Tranel, Wefel, & Barrash, 1997; 
Trueblood, 1994; Trueblood & Schmidt, 1993). On the other hand, the frequency of using the 
RMI was much higher than expected considering the limited number of studies that have 
examined the use of this measure as a tool for assessing response style. Of the limited 
research available to date since the initial development of the RMI by Killgore & DellaPietra 
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(2000), initial findings have not supported the RMI as a reliable indicator of detecting 
suspected exaggerators (Lange et al., in press; Lange et al., 2003; Langeluddecke & Lucas, 
2004). 
 There are several limitations of this study. One limitation is the small number of 
surveys returned. Only 17 people responded to the survey despite others being presented with 
three opportunities to do so. It is difficult to explain why the completion rate for this survey 
was low. One possibility is that the subject of symptom exaggeration is regarded by 
Australian neuropsychologists as only relevant to those working predominantly with medico-
legal cases. Since this is not the case for most Australian neuropsychologists, many clinicians 
may have perceived the survey as not relevant to them. Data from the minimal response 
section of this survey could not be used to shed light on the reasons for the low response rate 
because this section was typically not completed. In addition, because of the sampling method 
used in this study, it was not possible to calculate the response rate for this survey. Thus, it is 
difficult to comment on the representativeness of these results, beyond noting they appear to 
offer reasonable a geographical match with the distribution of APS, CCN members. Findings 
from this study should be interpreted as providing a general indication of practice trends only 
because of the use of a convenience sample. Future investigations should explore ways of 
improving survey participation. This could include the use of focus groups (as an alternative 
to surveying participants), conducting an exit poll of those who complete the survey to 
determine if there were particular reasons for participating (e.g., perceptions that the survey 
was particularly relevant), or the provision of incentives for participation, such as professional 
development points. 
 A second limitation of this study relates to the quality of the information obtained 
from respondents. The majority of respondents provided estimates of base rates rather than 
consulting data bases. Although similar published studies share this limitation (e.g., 
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Mittenberg et al., 2002), we attempted to improve data quality by encouraging respondents to 
refer to data bases when completing this survey. Since relatively few participants did this, 
future studies may need to explore why data bases were not consulted by more people.  
Alternatively, a prospective study may be needed so that base rates can be recorded as cases 
are processed avoiding the need to rely on best guesses, or a comparison of “estimated” and 
data base generated figures could be undertaken to determine the reliability of professionals’ 
opinions about malingering frequency. 
Despite these limitations, three strengths of this study should not be overlooked. First, 
until recently, symptom exaggeration base rates in Australia could only be derived from a 
handful of published studies on symptom exaggeration (e.g., Lange et al., in press; 
Langeluddecke & Lucas, 2004). This study presents base rate data from 14 different settings, 
across four Australian States, over a much larger number of cases than was previously the 
case.  Second, to our knowledge, this is the first study in Australia that reports symptom 
exaggeration test usage. Such information is important as it can inform professional 
development programs designed to ensure best practice in relation to the use of symptom 
exaggeration detection tasks. Third, this study clearly shows the extent of symptom 
exaggeration may vary internationally, even though there appears to be similarities in terms of 
patterns of symptom exaggeration related to diagnostic categories and setting. This suggests 
caution is needed when generalising North American symptom exaggeration base rates to 
Australia and possibly elsewhere.   
Overall, the importance of this study is reflected in the relationship between symptom 
exaggeration base rates and diagnostic accuracy. Without such information, diagnostic 
accuracy may be reduced.  Future studies of this type will be needed to ensure the currency of 
symptom exaggeration base rates across various setting types, geographic regions, and 
diagnostic categories.  
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Footnotes 
 1 As the base rate of malingering increases, so does the positive predictive power. 
Conversely, as malingering base rates decrease, so positive predictive power values decrease. 
 2 In a conference presentation at the National Academy of Neuropsychology, Lange, 
Senior, Douglas, & Dawes (2003) reported a 14.1% base rate of Malingered Neurocognitive 
Dysfunction (Slick, Sherman, & Iverson, 1999) in a sample of 64 head injury litigants of 
mixed severity. This sample was not the same sample as used by Lange et al. (in press). 
 3 Two participants submitted case type estimates that did not sum to 100%. Estimates 
were adjusted by 2.5% in both cases (i.e., added in one case and subtracted in the other case). 
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Table 1 
  
Demographic characteristics of survey respondents (N = 14) 
 
Note. aNo data were received from participants in Western Australia, Northern Territory, 
Australian Capital Territory, or Tasmania. bNo cases from University affiliated hospitals or 
clinics were reported.  
 
 
Region of Practicea % 
 New South Wales 36 
 Victoria 36 
 Queensland 14 
 South Australia 14 
   
Practice Settingb  
 Private practice 64 
 Hospital 36 
   
Percentage of annual referrals  
 Personal injury litigation 30 
 Disability or worker’s compensation claims 6 
 Criminal litigation 6 
 Medical or psychiatric not involving litigation 60 
   
Percentage of Personal injury or Disability Cases  
 Referred by plaintiff’s doctor or attorney 73 
 Referred by defendants attorney or insurer 24 
 Self-referred 4 
   
Percentage of criminal cases  
 Referred by defence attorney 60 
 Referred by prosecuting attorney 40 
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Table 2  
Estimated base rates of probable malingering or symptom exaggeration by referral type and 
practice setting 
Setting M (%) SD (%) 
Civil Cases   
 Private or group practice 13 13 
 Hospital (public or private)   9 10 
Criminal cases   
 Private or group practice 19 24 
 Hospital (public or private) a - - 
Medical or psychiatric cases not involving litigation or compensation   
 Private or group practice   4  6 
 Hospital (public or private)   3  2 
   
Referral Type   
Personal injury cases 13  12 
Disability or worker’s compensation  13  13 
Criminal  17  22 
Medical or psychiatric cases   3    5 
Note.   aA five percent estimate of malingering in annual cases seen in hospital settings 
involving criminal cases was reported by one participant.
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Table 3  
 
Base rates of probable malingering or symptom exaggeration in litigating or compensation 
seeking cases by diagnosis 
   Ranked position 
Diagnosis M (%) SD (%)  This 
study 
Mittenberg et 
al. (2002) 
Mild head injury 23 27  1 1 
Pain or somatoform disorders 15 27  2 3 
Moderate or severe head injury 15 27  3 10 
Fibromyalgia or chronic fatigue 15 29  4 2 
Depressive disorders 11 27  5 6 
Neurotoxic disorders 11 27  6 4 
Anxiety disorders 11 27  7 7 
Electrical injury 10 27  8 5 
Dissociative disorders 10 28  9 8 
Seizure disorders 9 27  10 9 
Vascular dementia 8 27  11 11 
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Table 4   
Percentage of diagnostic impressions supported by criteria in probable malingering or symptom exaggeration cases in order from highest to 
lowest 
Criteria  Ranked position 
 % This study Mittenberg 
et al. (2002) 
Severity of cognitive impairment inconsistent with condition 68 1 1 
Pattern of cognitive test performance inconsistent with condition 66 2 2 
Discrepancies among records, self-report, and observed behaviour 64 3 4 
Scores below empirical cutoffs on forced choice tests 59 4 3 
Implausible self-reported symptoms in interview 56 5 5 
Implausible changes in test scores across repeated examinations 44 6 7 
Scores below chance on forced choice tests 32 7 9 
Scores below empirical cutoffs on other malingering tests 30 8 6 
Scores above validity scale cutoffs on objective personality tests 24 9 8 
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Table 5  
Use of specialised malingering tests and methods to detect malingering derived from standard 
neuropsychological tests 
Specialised malingering tests % 
 Rey 15-item test 46 
 TOMM 41 
 Warrington recognition memory test 22 
 Other* 20 
 Work memory test 14 
 Validity indicator profile 2 
 Victoria symptom validity test <1 
 21-item test 0 
  
Malingering detection tools derived from standard neuropsychological tests  
 RAVLT recognition scores 24 
 Othera 22 
 WMS-III RMI 15 
 WMS-R/III attention–memory discrepancy scores  14 
 WAIS-R/III Digit span/ Vocabulary difference score 7 
 WCST Unique items 7 
 CVLT recognition scores 2 
 WAIS-R/III Reliable digits <1 
 RCFT Recognition trial 0 
Note. aExamples provided in text. 
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Appendix 
 
SECTION A: General Referral Information 
 
1. In which region do you practice? 
□ Western Australia  □ South Australia  □ Victoria  
□ New South Wales  □ Queensland  □ Tasmania  
□ Northern Territory   □ Australian Capital Territory  
 
2. Indicate one primary practice setting 
□ Private practice   □ Public or private hospital 
□ University 
□ Other (please specify) __________________________________________  
 
3. Do you currently practice clinical neuropsychology in Australia? □ Yes   □ No  
 
4. Which professional organisations are you a member of (tick all that apply)? 
□ Australian Psychological Society, College of Clinical Neuropsychology (APS, CCN) 
□ Australian Psychological Society, College of Forensic Psychologists  
□ Australian Society for the Study of Brain Impairment (ASSBI) 
□ International Neuropsychology Society (INS) 
□ National Academy of Neuropsychology (NAN)    
□ Other (please specify) __________________________________________  
 
5. _____ Years of clinical neuropsychology practice  
 
6. _____ Number of neuropsychological examinations interpreted monthly 
 
7. What percentage of total annual neuropsychological referrals involve the following: 
 
_____ % personal injury litigation  
_____ % disability or worker’s compensation claims 
_____ % criminal litigation 
_____ % medical or psychiatric not involving or seeking compensation 
 
8. What percentage of PERSONAL INJURY OR DISABILITY CASES are referred from the following 
sources: 
 
_____ % referred by treating doctor 
_____ % referred by plaintiff’s attorney 
_____ % referred by defence attorney or insurer 
_____ % self referred 
 
9. What percentage of CRIMINAL CASES are referred or requested by: 
 
_____ % defence 
_____ % prosecution 
 
 
 
 
If you are making a MINIMAL RESPONSE, please indicate why you have chosen not to complete the full 
questionnaire, in the space below. OTHERWISE, you are ready to commence the ethics part of this survey. 
SECTION B: Malingering Base Rates 
Symptom exaggeration in Australia 32 
 
10. What percentage of your annual cases in each category involve PROBABLE SYMPTOM 
EXAGGERATION OR MALINGERING? 
 
_____ % of personal injury cases 
_____ % of disability or worker’s compensation cases 
_____ % of criminal cases 
_____ % of medical or psychiatric cases not involved in litigation or seeking compensation 
 
11. What percentage of your LITIGATING OR COMPENSATION SEEKING CASES examined for the 
following disorders involve probable symptom exaggeration or malingering? 
 
_____ % of mild head injury claims 
_____ % of moderate or severe head injury claims 
_____ % of depressive disorder claims 
_____ % of anxiety disorder claims 
_____ % of pain or somatoform disorder claims 
_____ % of dissociative disorder claims 
_____ % of vascular dementia claims 
_____ % of seizure disorder claims 
_____ % of neurotoxic disorder claims 
_____ % of electrical injury claims 
_____ % of fibromyalgia or chronic fatigue claims  
 
12. In what percentage of your PROBABLE SYMPTOM EXAGGERATION OR MALINGERING CASES 
do each of the following support your impression? 
 
_____ % below empirical cut-off on forced choice tests 
_____ % below chance on forced choice tests 
_____ % below empirical cut-off on other malingering tests 
_____ % pattern of cognitive test performance does not make neuropsychological sense (inconsistent with 
condition) 
_____ % severity of cognitive impairment inconsistent with condition 
_____ % implausible changes in test scores repeated examinations 
_____ % above validity scale cut-offs on objective personality tests 
_____ % discrepancies among records, self-report, and observed behaviour 
_____ % implausible self-reported symptoms in interview 
 
SECTION C: Malingering Test Usage 
 
13. When assessing a case for litigation/workers compensation purposes, do you routinely assess for 
exaggeration and malingering? (please circle)   
YES  NO 
 
14. When assessing a case that DOES NOT involve litigation/workers compensation, do you routinely assess 
for exaggeration and malingering? (please circle)   
YES  NO 
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15. What methods do you use to assess for exaggeration and malingering?  
(Please number in order of importance starting with 1 for those methods that you routinely use). 
 
□ Tests specifically designed for detecting malingering (e.g., TOMM, Rey 15 Item) 
□ Measures/scores obtained from the administration of standard cognitive tests (e.g., WMS-III Rarely 
Missed Index, WAIS-III Reliable Digits, RAVLT Recognition) 
□ Behavioural observation/Interview 
 
16. Which tests designed to detect malingering do you routinely use for assessing exaggeration and 
malingering? Please indicate the percentage of cases you would use the test.  
 
_____ % Test of Memory Malingering (TOMM) 
_____ % Rey 15 Item Test (Rey-15) 
_____ % 21-item test (21-Item)  
_____ % Validity Indicator Profile (VIP) 
_____ % Work Memory Test (WMT) 
_____ % Warrington’s Recognition Memory Test (WRMT) 
_____ % Victoria symptom Validity Test (VSVT) 
_____% other (please indicate) ________________________________ 
 
17. Do you routinely use any of the following proposed malingering measures/indexes derived from the 
administration of standard cognitive tests? If so, please indicate the percentage of cases you would 
use the measure.  
 
_____ % WMS-III Rarely Missed Index (RMI) 
_____ % WAIS-III/WAIS-R: Reliable Digits  
_____ % WAIS-III/WAIS-R: Difference scores between Digit Span and Vocabulary 
_____ % WMS/WAIS: Suppressed attention versus memory discrepancy scores 
_____ % Rey Auditory Verbal Learning Test (RAVLT) Recognition scores 
_____ % California Verbal Learning Test (CVLT) Recognition scores 
_____ % Wisconsin Card Sort Test (WCST) Unique Items 
_____ % Rey Complex Figure Test (RCFT) Recognition trial 
_____ % other (please indicate) ___________________________________ 
 
 
 
Please indicate whether the percentages you indicated in this survey were provided based on (a) a statistical analysis of a 
database you maintain in your setting, or (b) your best estimate (please tick appropriate box). 
PART A: General Referral Information  □ Database   □ Best estimate  
PART B: Malingering Base Rates  □ Database   □ Best estimate 
PART C: Malingering Test Usage  □ Database   □ Best estimate 
  
 
 
 
 
 
